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Introduction
Treatment of juvenile idiopathic arthritis (JIA) has chan-
ged dramatically since the introduction of biologics in
1999. Because of more insight in the cytokines involved in
JIA the number of available biologic agents increased.
Together with the introduction of these new drugs, new
insights in the optimal treatment of JIA indicate that ear-
lier and more aggressive therapy is associated with better
outcomes. Whether these developments with regard to
biologic treatment have resulted in better patients’ out-
comes in daily practice is not yet reported.
Objectives
To evaluate trends in prescription of biologics and influ-
ence on outcomes of Dutch JIA patients that started their
first biologic between 1999 and 2010.
Methods
The Arthritis and Biologicals in Children register (a multi-
center prospective observational study) aims to include all
JIA patients in the Netherlands who use or used biologic
agents since 1999. Patients were divided in time periods
according to the year of introduction of first biologic
agent. Trends in characteristics of patients before intro-
duction of first biologic and effectiveness of the first biolo-
gic were analyzed over a 12 year period.
Results
343 non-systemic and 86 systemic JIA patients started at
least 1 biologic agent between 1999 and 2010. Etanercept
remained biologic of first choice for non-systemic JIA and
anakinra has become first choice for systemic JIA. The use
of systemic prednisone and synthetic disease-modifying
anti-rheumatic drugs (besides methotrexate) prior to bio-
logics decreased. During these 12 years of observation,
biologics were prescribed after shorter disease durations;
the proportion of patients with less than 1.5 years of dis-
ease duration before start of the first biologic agent
increased from zero in the years 1999-2001 to 31% in
2008-2010. Disease activity and acquired sequelae at base-
line decreased with regard to number of joints with arthri-
tis (median of 18 in 1999-2001 decreased to 5 in 2008-
2010), number of joints with limited motion (median of
12 in 1999-2001 decreased to 3 in 2008-2010) and func-
tional disability (CHAQ) scores (median score of 1.8 in
1999-2001 decreased to 1.1 in 2008-2010). In systemic JIA
biologics are now being introduced in patients with higher
ESR values. These changes resulted in more patients with
inactive disease and less joints with limited motion after
3 and 15 months of treatment in all JIA categories.
Conclusion
Biologics are prescribed increasingly, are introduced ear-
lier during the disease course and in JIA patients with
lower disease activity. These changes are accompanied by
better short-term disease outcomes. Etanercept remains1Erasmus MC Sophia Children’s Hospital, Rotterdam, Netherlands,
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